Acute and Chronic GVHD: Current Approaches, Near-Term Progress, and Future Directions

In this interactive 2-hour virtual webinar, expert faculty will use case-based discussions to highlight the latest treatment advances for patients with acute and chronic graft versus host disease (GVHD).

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.


  • Program Overview
  • Diagnostic and Prognostic Biomarkers in GVHD
  • Current and Evolving Prophylactic Strategies for GVHD
  • Managing Acute GVHD
  • Chronic GVHD Treatment Strategies
  • Adverse Event Management with GVHD
    • COVID and GVHD
  • Future Directions in GVHD Treatment
    • GVHD Updates From ASH 2021
  • Question and Answer Session and Closing Remarks


Date / Time
Event Details


Program Director
David Miklos, MD, PhD

Professor of Medicine
Blood Marrow Transplantation and Cancer Cell Therapy
Stanford University
Stanford, California

Corey Cutler, MD, MPH, FRCPC

Associate Professor of Medicine
Harvard Medical School
Medical Director, Stem Cell Transplantation
Dana-Farber Cancer Institute
Boston, Massachusetts

Robert Zeiser, MD

Professor of Medicine
Department of Hematology and Oncology
Division of Tumor Immunology
Department of Internal Medicine
Freiburg University Medical Center
Freiburg, Germany

Goal Statement
The goal of this activity is to improve the knowledge and competence of learners in treating patients with hematologic malignancies with or at risk of developing GVHD.

Target Audience
This program is intended for physicians and other healthcare professionals involved in the management of GVHD.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Review recent advances in our understanding of the underlying pathophysiology of GVHD and the rationale for the use of novel therapies for the treatment of patients with or at risk of developing GVHD
  • Evaluate current and emerging clinical trial data evaluating the use of recently FDA-approved agents for acute, chronic, steroid-naive, or steroid-refractory GVHD
  • Recognize adverse events and toxicities associated with prophylactic strategies and therapeutic approaches and use this information to develop supportive care plans for patients with GVHD
  • Identify patients at risk of GVHD who are candidates for ongoing clinical trials evaluating emerging options for prophylaxis and management


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.